Evidence map›Paper›PMID 39030507›Full record

ArticleBMC cancer2024

Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma.

Qianqian Cheng, Wenbin Ji, Zhenyu Lv, Wei Wang, Zhaiyue Xu, Shaohua Chen, Wenting Zhang, Yu Shao, Jing Liu, Yan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qianqian Cheng *Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Wenbin Ji *Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Zhenyu LvDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Wei WangDepartment of Gastroenterology, The Third People's Hospital of Bengbu, 233004, Bengbu, China.
Zhaiyue XuSchool of Medical, Southeast University, 210000, Nanjing, China.
Shaohua ChenDepartment of Pathology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Wenting ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Yu ShaoNational Drug Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Jing LiuDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China.
Yan YangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, 233004, Bengbu, China. qiannianhupo@163.com.

Funding

The 512 Talent Cultivation Plan of Bengbu Medical University No. by51202208The Excellent Youth Talents Support Program in Higher Education Institutions of Anhui Province No. gxyq2022042The Natural Science Research Major Project of Universities of Anhui Province No. 2023AH040291The Science Fund for Distinguished Young Scholars of the First Affiliated Hospital of Bengbu Medical University No. 2019byyfyjq02
6 · The paper itself

Abstract

objectiveCancer is a predominant cause of death globally. PHD-finger domain protein 5 A (PHF5A) has been reported to participate in various cancers; however, there has been no pan-cancer analysis of PHF5A. This study aims to present a novel prognostic biomarker and therapeutic target for cancer treatment.

methodsThis study explored PHF5A expression and its impact on prognosis, tumor mutation burden (TMB), microsatellite instability (MSI), functional status and tumor immunity across cancers using various public databases, and validated PHF5A expression and its correlation with survival, immune evasion, angiogenesis, and treatment response in hepatocellular carcinoma (HCC) using bioinformatics tools, qRT-PCR and immunohistochemistry (IHC).

resultsPHF5A was differentially expressed between tumor and corresponding normal tissues and was correlated with prognosis in diverse cancers. Its expression was also associated with TMB, MSI, functional status, tumor microenvironment, immune infiltration, immune checkpoint genes and tumor immune dysfunction and exclusion (TIDE) score in diverse malignancies. In HCC, PHF5A was confirmed to be upregulated by qRT-PCR and IHC, and elevated PHF5A expression may promote immune evasion and angiogenesis in HCC. Additionally, multiple canonical pathways were revealed to be involved in the biological activity of PHF5A in HCC. Moreover, immunotherapy and transcatheter arterial chemoembolization (TACE) worked better in the low PHF5A expression group, while sorafenib, chemotherapy and AKT inhibitor were more effective in the high expression group.

conclusionsThis study provides a comprehensive understanding of the biological function of PHF5A in the carcinogenesis and progression of various cancers. PHF5A could serve as a tumor biomarker related to prognosis across cancers, especially HCC, and shed new light on the development of novel therapeutic targets.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsGene Expression Regulation, NeoplasticHumansMicrosatellite InstabilityMolecular Targeted TherapyPrognosisRNA-Binding ProteinsTrans-ActivatorsTumor MicroenvironmentBiomarkers, TumorPHF5A protein, humanRNA-Binding ProteinsTrans-ActivatorsAngiogenesisHepatocellular carcinomaPan-cancerPrognosisTreatment responseTumor immunity

Identifiers

PMID39030507
PMCPMC11264801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.